Affordable Access

deepdyve-link
Publisher Website

Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.

Authors
  • von Wyl, Viktor1
  • Yerly, Sabine
  • Böni, Jürg
  • Bürgisser, Philippe
  • Klimkait, Thomas
  • Battegay, Manuel
  • Bernasconi, Enos
  • Cavassini, Matthias
  • Furrer, Hansjakob
  • Hirschel, Bernard
  • Vernazza, Pietro L
  • Rickenbach, Martin
  • Ledergerber, Bruno
  • Günthard, Huldrych F
  • 1 Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland. [email protected] , (Switzerland)
Type
Published Article
Journal
Clinical Infectious Diseases
Publisher
Oxford University Press
Publication Date
Apr 15, 2008
Volume
46
Issue
8
Pages
1299–1309
Identifiers
DOI: 10.1086/528863
PMID: 18444871
Source
Medline
Language
English
License
Unknown

Abstract

The human immunodeficiency virus type 1 reverse-transcriptase mutation K65R is a single-point mutation that has become more frequent after increased use of tenofovir disoproxil fumarate (TDF). We aimed to identify predictors for the emergence of K65R, using clinical data and genotypic resistance tests from the Swiss HIV Cohort Study. A total of 222 patients with genotypic resistance tests performed while receiving treatment with TDF-containing regimens were stratified by detectability of K65R (K65R group, 42 patients; undetected K65R group, 180 patients). Patient characteristics at start of that treatment were analyzed. In an adjusted logistic regression, TDF treatment with nonnucleoside reverse-transcriptase inhibitors and/or didanosine was associated with the emergence of K65R, whereas the presence of any of the thymidine analogue mutations D67N, K70R, T215F, or K219E/Q was protective. The previously undescribed mutational pattern K65R/G190S/Y181C was observed in 6 of 21 patients treated with efavirenz and TDF. Salvage therapy after TDF treatment was started for 36 patients with K65R and for 118 patients from the wild-type group. Proportions of patients attaining human immunodeficiency virus type 1 loads <50 copies/mL after 24 weeks of continuous treatment were similar for the K65R group (44.1%; 95% confidence interval, 27.2%-62.1%) and the wild-type group (51.9%; 95% confidence interval, 42.0%-61.6%). In settings where thymidine analogue mutations are less likely to be present, such as at start of first-line therapy or after extended treatment interruptions, combinations of TDF with other K65R-inducing components or with efavirenz or nevirapine may carry an enhanced risk of the emergence of K65R. The finding of a distinct mutational pattern selected by treatment with TDF and efavirenz suggests a potential fitness interaction between K65R and nonnucleoside reverse-transcriptase inhibitor-induced mutations.

Report this publication

Statistics

Seen <100 times